Accendra Health (NYSE:ACH – Get Free Report) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Monday, Zacks reports.
A number of other equities research analysts have also recently issued reports on the company. UBS Group decreased their target price on Accendra Health from $4.50 to $1.50 and set a “neutral” rating for the company in a research report on Thursday, August 13th. Weiss Ratings lowered shares of Accendra Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th. Robert W. Baird set a $1.50 price objective on shares of Accendra Health and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Finally, Citigroup cut shares of Accendra Health from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $4.50 to $1.50 in a research note on Monday, August 10th. Three research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Accendra Health has a consensus rating of “Reduce” and an average target price of $1.50.
View Our Latest Research Report on ACH
Accendra Health Stock Up 2.6%
Accendra Health (NYSE:ACH – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.06). Accendra Health had a negative return on equity of 4.02% and a negative net margin of 11.41%.The company had revenue of $613.23 million for the quarter. As a group, equities analysts forecast that Accendra Health will post -0.03 earnings per share for the current fiscal year.
Institutional Trading of Accendra Health
A number of hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LP bought a new position in shares of Accendra Health during the 2nd quarter worth about $40,000. Public Employees Retirement System of Ohio bought a new stake in shares of Accendra Health in the second quarter valued at about $96,000. Bank of America Corp DE bought a new stake in shares of Accendra Health in the second quarter valued at about $12,912,000. Man Group plc acquired a new stake in Accendra Health during the second quarter worth about $436,000. Finally, The Manufacturers Life Insurance Company bought a new position in Accendra Health during the second quarter valued at about $68,000.
About Accendra Health
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services.
See Also
- Five stocks we like better than Accendra Health
- The AI Boom’s Next Big Winners May Wear Hard Hats
- Rivian Escapes the EV Graveyard—But Can It Stay Alive?
- Allient’s Data Center and Defense Momentum Is Raising the Stakes
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
Receive News & Ratings for Accendra Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accendra Health and related companies with MarketBeat.com's FREE daily email newsletter.